Former FDA/OTC Review Director Robert Pinco
Attorney with Washington, D.C. firm Baker & Hostetler reportedly hopes to return to agency as top-level assistant to Commissioner Young. Although he had "no comment" for "The Pink Sheet," Pinco is said to have visited Capitol Hill to garner support for a return to FDA. James Benson has been acting deputy commissioner since June 1988. When Benson took the job, he was believed to be doing it on a temporary basis with the hope that he could return to his previous post as deputy director at the Center for Devices and Radiological Health. That job has not been filled on a permanent basis.
You may also be interested in...
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.